Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.78 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA9 | Q16790 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311637 | 0.98 | TDP1 (0.75) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL14723706 | 0.93 | TDP1 (0.66) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL4439416 | 0.91 | TDP1 (0.65) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL133020 | 0.88 | TDP1 (1.00) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL2819924 | 0.88 | TDP1 (1.00) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL5193445 | 0.88 | TDP1 (1.00) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL7908254 | 0.88 | TDP1 (1.00) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL22777078 | 0.88 | TDP1 (1.00) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL5133849 | 0.88 | TDP1 (1.00) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL15508929 | 0.88 | TDP1 (1.00) | TDP1MAOAMAOBCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190943-A1 | ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-3770180-A1 | ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND | Mochida Pharmaceutical Co., Ltd. (JP) | 2021-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190943-A1 | ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND | ALG1, ALG8, ALG3 | TDP1 2939/4885MAOA 2485/4885MAOB 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.